Protalix BioTherapeuticsCompany Review & Valuation

PLX
Tel-Aviv Stock Exchange
Latest Price
1,270.00ILS
Market Capitalization
41.20bILS

About Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers Elelyso, a plant cell expressed recombinantShow more glucocerebrosidase enzyme for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials to treat Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that is in phase IIa clinical trials for the treatment of cystic fibrosis; and OPRX-106, an oral anti TNF product candidate, which is in Phase IIa clinical trial for the treatment of ulcerative colitis. Protalix BioTherapeutics, Inc. was founded in 1993 and is based in Karmiel, Israel.Show less

Industry
Biotechnology
HQ Location
Karmiel, Israel

Stock Price

Price data not available for Protalix BioTherapeutics.

Performance

Please login or create a free account to view the contents of this section.

Similar Companies

AGTC
argenx
Ovoca Bio
KalVista Pharmaceuticals

back to top